CARDIOCARE is pioneering a patient-centered, AI-powered healthcare model that integrates cardiology, oncology, psychology, digital health, and real-world data to proactively manage cardiotoxicity and quality of life in elderly breast cancer patients with multiple chronic conditions 

The clinical trial combines multimodal data streams — including wearable sensors, imaging, biomarkers, and patient-reported outcomes — into explainable AI-driven risk models that enable dynamic, personalized care planning throughout the entire cancer care journey. 

With over 600 patients recruited and strong clinical acceptance across Europe, CARDIOCARE is building the foundations for a scalable, ethically governed, and sustainable cardio-oncology care framework that could transform clinical practice, policy, and patient outcomes. 

A simple intervention, similar to the tension applied to the arm during a blood pressure reading, is being tested to see if it can reduce the risk of heart failure in cancer survivors treated with common cancer drugs, anthracyclines 

A phase II clinical trial to test the intervention has already recruited 355 people, with 608 patients across Europe expected to take part across six countries and 22 hospitals 

This is the first time an intervention has been offered to cancer patients during their treatment that could reduce their long-term chances of heart failure 

3 million Europeans receive anthracyclines as part of their cancer treatment each year. One million people in Europe are currently living with chronic heart failure following cancer therapy-related heart damage, or cardiotoxicity.